文献速递甲状腺疾病

重新审视分化良好型甲状腺癌中肿瘤大小与风险的关系

Revisiting the Relationship Between Tumor Size and Risk in Well-Differentiated Thyroid Cancer.
PubMed 文献 · Thyroid · 2024-07-24

基于美国国家癌症数据库(2010-2015)193,133例分化良好型甲状腺癌患者,肿瘤>4 cm者占7.9%。倾向评分匹配后,肿瘤>4 cm与更差生存独立相关(HR 1.63,p<0.001);但>4 cm合并其他高危特征时生存更差。按1 cm递增评估,死亡风险增幅最大出现在2 cm和5 cm,而非4 cm。验证队列结果基本一致。

要点

  • 肿瘤>4 cm与更差生存独立相关(HR 1.63,p<0.001)。
  • >4 cm合并其他高危特征者生存差于仅有>4 cm或仅有其他高危特征者。
  • 按1 cm递增分析,死亡风险增幅最大在2 cm和5 cm,而非4 cm。

核心结论

  • 合并高危特征比单纯大肿瘤带来更差的生存,4 cm切点并非风险增幅最大的位置。
  • 这些发现支持在分化良好型甲状腺癌管理中对肿瘤大小采取更细致的评估方式。

研究设计与样本

  • 从美国国家癌症数据库(2010-2015)识别分化良好型甲状腺癌患者,按肿瘤大小(小:≤4 cm;大:>4 cm)及高危组织病理特征(如甲状腺外侵犯)分类。
  • 采用倾向评分匹配识别除肿瘤大小外其他观察特征相似的患者,并用多变量Cox比例风险模型估计肿瘤大小与生存的关系。
  • 通过交互项评估高危特征对生存的条件效应是否取决于肿瘤>4 cm,并评估肿瘤大小每增加1 cm与生存的关系。
  • 使用监测、流行病学和最终结果计划(2008-2013)的验证队列重复分析。
  • 主要队列共193,133例患者。

主要发现

  • 主要队列中7.9%的患者肿瘤>4 cm,30%的患者至少有一种高危特征。
  • 匹配后,肿瘤>4 cm与更差生存独立相关(HR 1.63,p<0.001)。
  • 肿瘤>4 cm合并一种或以上其他高危特征者的生存差于仅有肿瘤>4 cm者(MMD:0.70,p<0.001),也差于仅有其他高危特征者(MMD:0.49,p<0.001)。
  • 按1 cm递增评估时,死亡风险增幅最大出现在2 cm和5 cm,而非4 cm。
  • 验证队列结果与主要发现基本一致。

临床怎么用

  • 原文结论指出这些发现支持在分化良好型甲状腺癌管理中对肿瘤大小采取更细致的评估方式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Introduction: Large tumor size is associated with poorer outcomes in well-differentiated thyroid cancer, yet it remains unclear whether size >4 cm alone confers increased risk, independent of other markers of aggressive disease. The goal of this study was to assess the relationship between tumor size, other high-risk histopathological features, and survival in well-differentiated thyroid cancer and to evaluate the significance of 4 cm as a cutoff for management decisions. Methods: Patients with well-differentiated thyroid cancer were identified from the National Cancer Database (2010-2015) and categorized by tumor size (i.e., small [≤4 cm] or large [>4 cm]) and presence of high-risk histopathological features (e.g., extrathyroidal extension). First, propensity score matching was used to identify patients who were similar across all other observed characteristics except for small versus large tumor size, and a multivariable Cox proportional hazards model was used to estimate the relationship between tumor size and survival. Second, we assessed whether the presence of high-risk features demonstrates conditional effects on survival based on the presence of tumor size >4 cm using an interaction term. Finally, additional models assessed the relationship between incremental 1 cm increases in tumor size and survival. Analyses were repeated using a validation cohort from the Surveillance, Epidemiology, and End Results Program (2008-2013). Results: Of 193,133 patients in the primary cohort, 7.9% had tumors >4 cm, and 30% had at least one high-risk feature. After matching, tumor size >4 cm was independently associated with worse survival (HR 1.63, p < 0.001). However, tumor size >4 cm and one or more other high-risk features together yielded worse survival than either size >4 cm alone (MMD: 0.70, p < 0.001) or other high-risk features alone (MMD: 0.49, p < 0.001). When assessed in 1 cm increments, the largest increases in hazard of death occurred at 2 cm and 5 cm, not 4 cm. Results from the validation cohort were largely consistent with our primary findings. Conclusions: Concomitant high-risk features confer worse survival than large tumor size alone, and a 4 cm cutoff is not associated with the greatest increase in risk. These findings support a more nuanced approach to tumor size in the management of well-differentiated thyroid cancer.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Ginzberg SP, Sharpe J, Passman JE, et al. Revisiting the Relationship Between Tumor Size and Risk in Well-Differentiated Thyroid Cancer. Thyroid. 2024. PMID: 38877803. doi:10.1089/thy.2023.0327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。